

Neuberger Berman Equity Research Team

SENIOR HEALTH CARE ANALYST: Terri L. Towers, PhD

COVID-19 Update: News on Vaccines, Views from Dr. Gottlieb

Vaccine Developments

This past weekend brought various news tied to COVID-19 vaccine trials, including Oxford University/AstraZeneca vaccine trial restarts, Moderna updates to enrollment, Pfizer expanding enrollment to include a broader population and Merck trials getting going.

- Moderna updated enrollment in its Phase 3 study late Friday night with 23,497 participants having now enrolled, or an increase of 2,086 over the prior week compared to enrollment increases of 3,953 and 4,264 in the previous two weeks. The company stated that ~27% of enrollees are from diverse communities.
- Pfizer expanded enrollment in its Phase 3 COVID-19 study to include younger patients (16 – 18 yrs.) as well as older patients, suggesting to us that safety to date looks unremarkable.
- Merck initiated its Phase 1/2 trials with COVID-19 vaccine candidate V591, dosing volunteers in Belgium, according to an article in *The Wall Street Journal*. Recall that Merck had been criticized for being “late to the party,” but we tend to agree with CEO Kenneth Frazier that careful selection of the right platform could prove advantageous in the long run and view their attenuated measles vector system as affording broader responses from both antibodies and T cells.

Scott Gottlieb's Take on COVID-19

Dr. Gottlieb, the former Food and Drug Administration commissioner, has been making the rounds on the virus and COVID-19. In a recent opinion piece, he reiterated his views on a staged rollout of the vaccine, saying he still believes Pfizer-BioNTech will have data in mid-October despite increasing/broadening enrollment in their vaccine trial. Regarding the Trump administration's influence on vaccine approval and launch, he pushed back on conspiracy theories and doesn't see an emergency use authorization (EUA) before the November 3 election in either case, given tight timelines. Dr. Gottlieb also thinks that the October 22 FDA advisory meeting will focus on guidelines more than anything else. Below are key comments from Dr. Gottlieb that we found incremental from a timeline and approval-hurdle perspective:

- Safety concerns regarding the Oxford University/Astra Zeneca vaccine are rational given adenoviral vectors and their association with inflammatory/neurological reactions such as Guillain Barre and transverse myelitis; he believes they are more likely due to the platform rather than the antigen (Spike protein).
- A EUA guidance document is coming out in a few weeks and should opine on the number of patients, with at least 6-8 weeks of follow-up safety data required in order for an EUA to be granted.
- Dr. Gottlieb is leaning towards SARS-CoV2 (the virus that causes COVID-19) becoming seasonal, with higher spread this fall and winter, a decline in spring 2021 but a resurgence in fall 2021. However, he projects that at least 20% of the U.S. population will have been infected by fall 2021 outside of vaccination, so the spread may be a bit slower when coupled with mask wearing and social distancing.
- On efficacy, antibodies are key in his view. T cells will help in responding to second infections should they occur, but he cautioned that they will not protect from infection but just diminish the severity of COVID-19. He thinks sterilizing immunity from vaccines will not occur, so he is bullish on the outlook for recombinant antibody therapeutics. To this end, he expects initial viral load data by the end of September and, if positive, thinks the vast safety database on recombinant antibodies could give FDA comfort on early approval if need be, and he is in agreement with our house view that odds are better for utility in early disease and prophylaxis vs. treatment setting.
- Finally, on what is evolving as a COVID-19 syndrome, Dr. Gottlieb is disappointed regarding the availability of other clinical sequelae data from the CDC database (or lack thereof), views reported cardiac adverse events as perhaps initially misdiagnosed for pulmonary issues (i.e. emboli vs. pneumonia) and thinks more aggressive treatment of clotting disorders to will help decrease mortality going forward.

Where Do We Stand on the Pandemic?

With the number of new daily cases in the U.S. stubbornly stable at around 38,000 – 40,000 per day, despite back-to-school spikes and a gradual return to a new “normal,” we think that daily tracking will be less important going forward.

We view the hospitalization data as encouraging, demonstrating lessons learned from months ago on how to better treat COVID-19 patients (we think steroids and anticoagulants have had the most impact) as well as a case fatality rate of ~3% as reasons for some optimism as we await recombinant antibody biomarker data expected by the end of September and initial vaccine data in mid- to late October.

While SARS-CoV2 will likely remain in circulation for the next few years, reinfection data coupled with our view that T-cell responses triggered by vaccination could lessen the severity of COVID-19 all contribute to our growing confidence that this virus may eventually become more of a nuisance virus, similar to the other four coronaviruses that cause a bad cold. We are carefully monitoring the current second waves in Spain, France and the U.K. for evidence of a less severe course of COVID-19, which could add to our view of memory responses from natural infection, which should likely be more pronounced post-vaccination.

This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. This material is general in nature and is not directed to any category of investors and should not be regarded as individualized, a recommendation, investment advice or a suggestion to engage in or refrain from any investment-related course of action. Investment decisions and the appropriateness of this material should be made based on an investor's individual objectives and circumstances and in consultation with his or her advisors. Information is obtained from sources deemed reliable, but there is no representation or warranty as to its accuracy, completeness or reliability. All information is current as of the date of this material and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. This material may include estimates, outlooks, projections and other “forward-looking statements.” Due to a variety of factors, actual events may differ significantly from those presented. Neuberger Berman products and services may not be available in all jurisdictions or to all client types. Diversification does not guarantee profit or protect against loss in declining markets. Investing entails risks, including possible loss of principal. Indexes are unmanaged and are not available for direct investment. **Past performance is no guarantee of future results.**

Discussions of any specific sectors and companies are for informational purposes only. This material is not intended as a formal research report and should not be relied upon as a basis for making an investment decision. The firm, its employees and advisory accounts may hold positions of any companies discussed. Nothing herein constitutes a recommendation to buy, sell or hold a security. Specific securities identified and described do not represent all of the securities purchased, sold or recommended for advisory clients. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.

The views of the research analyst and the firm and its employees on medical topics should not be relied upon as medical advice and are not intended to serve as a substitute for consulting with a qualified medical professional. There is no representation or warranty as to its accuracy, completeness or reliability. All information is current as of the date of the material and is subject to change without notice. The firm, its employees and advisory accounts may hold positions of the manufacturers of the products discussed.

For more information on COVID-19, please refer to the Center for Disease Control and Prevention at [cdc.gov](https://www.cdc.gov).

This material is being issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications for the specific entities and jurisdictional limitations and restrictions

The “Neuberger Berman” name and logo are registered service marks of Neuberger Berman Group LLC.

© 2020 Neuberger Berman Group LLC. All rights reserved.